A.30 is basically dead, well outcompeted by Delta etc. The UK don't report on it now.
"VUI-21FEB-01 (A.23.1 with E484K), VOC-21FEB-02 (B.1.1.7 with E484K), VUI-21MAR-01, (B.1.324.1 with E484K), A.30, B.1.633, B.1.214.2 and B.1.1.7 with S494P have not been observed in the UK or within the international GISAID dataset within the last 12 weeks. These variants are no longer included in the data update."
One of the best (IMHO) Sci-Fi books "His Master's Voice" by Stanisław Lem begins exactly like this.
"It is a densely philosophical first contact story about an effort by scientists to decode, translate, and understand an extraterrestrial transmission. The novel critically approaches humanity's intelligence and intentions in deciphering and truly comprehending a message from outer space."
https://en.wikipedia.org/wiki/His_Master%27s_Voice_(novel)
They evaluated "the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in challenge studies with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor" https://www.cell.com/cell/fulltext/S0092-8674(20)31068-0
Results
A total of 192 children (mean age 10.2 +/- 7 years) were enrolled. Forty-nine children (26%) were diagnosed with acute SARS-CoV-2 infection; an additional 18 children (9%) met criteria for MIS-C. Only 25 (51%) of children with acute SARS-CoV-2 infection presented with fever; symptoms of SARS-CoV-2 infection, if present, were non-specific. Nasopharyngeal viral load was highest in children in the first 2 days of symptoms, significantly higher than hospitalized adults with severe disease (P = .002). Age did not impact viral load, but younger children had lower ACE2 expression (P=0.004). IgM and IgG to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein were increased in severe MIS-C (P<0.001), with dysregulated humoral responses observed.
Conclusion
This study reveals that children may be a potential source of contagion in the SARS-CoV-2 pandemic in spite of milder disease or lack of symptoms, and immune dysregulation is implicated in severe post-infectious MIS-C.
BOSTON - In the most comprehensive study of COVID-19 pediatric patients to date, Massachusetts General Hospital (MGH) and Mass General Hospital for Children (MGHfC) researchers provide critical data showing that children play a larger role in the community spread of COVID-19 than previously thought. In a study of 192 children ages 0-22, 49 children tested positive for SARS-CoV-2, and an additional 18 children had late-onset, COVID-19-related illness. The infected children were shown to have a significantly higher level of virus in their airways than hospitalized adults in ICUs for COVID-19 treatment.
While recent research has shown that cannabis access laws can reduce the use of prescription opioids, the effect of these laws on opioid use is not well understood for all dimensions of use and for the general United States population. Analyzing a dataset of over 1.5 billion individual opioid prescriptions between 2011 and 2018, which were aggregated to the individual provider-year level, we find that recreational and medical cannabis access laws reduce the number of morphine milligram equivalents prescribed each year by 11.8 and 4.2 percent, respectively. These laws also reduce the total days’ supply of opioids prescribed, the total number of patients receiving opioids, and the probability a provider prescribes any opioids net of any offsetting effects. Additionally, we find consistent evidence that cannabis access laws have different effects across types of providers, physician specialties, and payers.
One "COVID‐19 and Vitamin D" study recommends treatment of COVID‐19 patients with high dose of vitamin D - 200,000 IU of vitamin D2 or vitamin D3 when admitted with COVID-19 followed by 4,000-10,000 IU/day - since populations most vulnerable to COVID-19 are likely vitamin D deficient (https://news.ycombinator.com/item?id=24132440)
Another study (cited by Deva Boone) discusses Vitamin D deficiency is a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19: 81% of patients had hypovitaminosis D; severe vitamin D deficiency patients had a 50% mortality probability, while those with vitamin D ≥ 10 ng/mL had a 5% mortality risk (https://news.ycombinator.com/item?id=24109396)
The negative outcomes of COVID‐19 diseases respiratory distress (ARDS) and the damage to other organs are secondary to a “cytokine storm” and to the attendant oxidative stress. Active hydroxyl‐forms of vitamin D are anti‐inflammatory, induce anti‐oxidative responses, and stimulate innate immunity against infectious agents. These properties are shared by calcitriol and the CYP11A1‐generated non‐calcemic hydroxyderivatives. They inhibit the production of pro‐inflammatory cytokines, downregulate NF‐κΒ, show inverse agonism on RORγ and counteract oxidative stress through the activation of NRF‐2. Therefore, a direct delivery of hydroxyderivatives of vitamin D deserves consideration in the treatment of COVID‐19 or ARDS of different etiology. We also recommend treatment of COVID‐19 patients with high dose vitamin D since populations most vulnerable to this disease are likely vitamin D deficient and patients are already under supervision in the clinics. We hypothesize that different routes of delivery (oral and parenteral) will have different impact on the final outcome.